Long-term outcome after discontinuation of CGRP monoclonal antibodies therapy for migraine: A narrative review.

Migraine is a common and debilitating neurological condition. Many people suffer from chronic migraine, which greatly affects their daily lives. Recently, new treatments using calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) have changed migraine prevention. These treatments are backed by strong evidence from clinical trials. However, guidelines often suggest stopping these treatments after a certain time. There is limited information about what happens when patients stop using these medications. This review looks at evidence from studies on the effects of discontinuing anti-CGRP mAb treatments. It finds that within three months of stopping, migraine symptoms often worsen. Many patients see their migraine burden return to previous levels. However, some patients may continue to experience benefits even after stopping treatment. This highlights the need for more research on long-term outcomes after stopping CGRP therapies. Clinical relevance: This review indicates that stopping CGRP monoclonal antibodies may lead to worsened migraine symptoms for many patients.